Opdivo Qvantig vs Pembrolizumab berahyaluronidase alfa
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT05722015 · Phase 3 · active, not recruiting
Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.
Next expected readout: December 2029 · NCT07190248 (registry estimate)
Reported efficacy
Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)
Result source: NCT05722015
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Opdivo Qvantig | Pembrolizumab berahyaluronidase alfa |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT05722015 |
| OS, median | —Not reported | —Trial running · NCT05722015 |
| ORR | —Not reported | 64.3% vs 18.2%vs PembrolizumabNCT06212752 |
| Duration of response, median | —Not reported | —Trial running · NCT05722015 |
PFS, median
- Opdivo Qvantig
- —Not reported
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
OS, median
- Opdivo Qvantig
- —Not reported
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
ORR
- Opdivo Qvantig
- —Not reported
- Pembrolizumab berahyaluronidase alfa
- 64.3% vs 18.2%vs PembrolizumabNCT06212752
Duration of response, median
- Opdivo Qvantig
- —Not reported
- Pembrolizumab berahyaluronidase alfa
- —Trial running · NCT05722015
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Opdivo Qvantig: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Opdivo Qvantig: 0 of 4 rows · Pembrolizumab berahyaluronidase alfa: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Pembrolizumab berahyaluronidase alfa |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT05722015 · Phase 3 · combination show 1 more resultn/a: no completion milestone NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | —a NCT05722015 · Phase 3 · combination show 1 more result— NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 39%a NCT05722015 · Phase 3 · combination show 1 more result42.9% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | show 1 more resultneutropenia 46.4% anaemia 42.9% constipation 39.3% NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab berahyaluronidase alfa
Melanoma
Shared mechanism: PD-1 · full Melanoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT06099782 · Phase 2 · active, not recruiting
Patients were randomized to the order in which they received the two routes, but the study was open-label, and its primary endpoint was the share of patients who preferred the subcutaneous route, a single percentage with no formal comparison. It measured preference and convenience, not whether the drug controls cancer, so it is limited evidence.
No aligned efficacy figure on record for this race.
Results for Melanoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Melanoma.
Pembrolizumab berahyaluronidase alfa: registry results are on file for Melanoma, but their comparison mappings are not yet available.
Renal Cell Carcinoma
Shared mechanism: PD-1 · full Renal Cell Carcinoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pembrolizumab berahyaluronidase alfa · Keytruda Qlex
Marketed by Merck & Co.
NCT06099782 · Phase 2 · active, not recruiting
Patients were randomized to the order in which they received the two routes, but the study was open-label, and its primary endpoint was the share of patients who preferred the subcutaneous route, a single percentage with no formal comparison. It measured preference and convenience, not whether the drug controls cancer, so it is limited evidence.
No aligned efficacy figure on record for this race.
Results for Renal Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: registry results are on file for Renal Cell Carcinoma, but their comparison mappings are not yet available.
Pembrolizumab berahyaluronidase alfa: registry results are on file for Renal Cell Carcinoma, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Opdivo Qvantig's landscape · Pembrolizumab berahyaluronidase alfa's landscape